Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
00%
Est. open job positions.
Loading...

Is Moleculin Biotech Hiring?

Moleculin Biotech (MBRX) currently has 0 active job postings, up 0.0% over the past three months. Hiring has been relatively stable over this window. Its headcount is around 22, according to LinkedIn data.

With 0 active postings, Moleculin Biotech trails industry peers like Amgen (1,486) and Gilead Sciences (647).

Why Hiring Trends Matter for MBRX Stock

Job posting trends are one of the earliest reads on a company’s operational direction: companies often ramp hiring before revenue accelerates and pull back before earnings disappoint. AltIndex feeds Moleculin Biotech’s job-posting count into the MBRX AI Score as one of 25+ alternative data signals, weighed alongside web traffic, sentiment, and fundamentals.

For related employment signals, see Moleculin Biotech’s headcount (according to LinkedIn data), and overall employee rating.

Month over Month Job Posts

Sep 2026 0
Aug 2026 0
Jun 2026 1
May 2026 1
Apr 2026 1
Feb 2026 0
Get MBRX alerts in real-time
The moment the job posts trend turns, sentiment flips, or insiders trade.
Try Stock Alerts Free

Moleculin Biotech Job Postings: Frequently Asked Questions

Moleculin Biotech currently has 0 active job postings, based on AltIndex’s daily count of its open LinkedIn listings. This is up 0.0% compared with three months ago.

Moleculin Biotech’s hiring pace has been relatively stable over the past three months. Its headcount stands at 22, according to LinkedIn data.

No single signal predicts a stock on its own, but hiring is a useful leading indicator: companies tend to add roles when they expect growth and freeze them when they don’t. AltIndex combines MBRX’s job-posting trend with 25+ other signals in the AI Score rather than reading any one signal in isolation.

Moleculin Biotech underperforms its industry peers when it comes to Job Posts, ranking dead last.

Sign up and get more insights on Moleculin Biotech.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.